25 XP   0   0   10

Abliva AB
Buy, Hold or Sell?

Let's analyse Abliva together

PenkeI guess you are interested in Abliva AB. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Abliva AB. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Abliva AB

I send you an email if I find something interesting about Abliva AB.

Quick analysis of Abliva (30 sec.)










What can you expect buying and holding a share of Abliva? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr0.07
Expected worth in 1 year
kr-0.02
How sure are you?
27.5%

+ What do you gain per year?

Total Gains per Share
kr-0.09
Return On Investment
-54.7%

For what price can you sell your share?

Current Price per Share
kr0.16
Expected price per share
kr0.14 - kr0.1902
How sure are you?
50%

1. Valuation of Abliva (5 min.)




Live pricePrice per Share (EOD)

kr0.16

Intrinsic Value Per Share

kr-0.57 - kr-0.08

Total Value Per Share

kr-0.51 - kr-0.01

2. Growth of Abliva (5 min.)




Is Abliva growing?

Current yearPrevious yearGrowGrow %
How rich?$6.4m$12m-$1.9m-19.4%

How much money is Abliva making?

Current yearPrevious yearGrowGrow %
Making money-$2.1m-$1.9m-$182.2k-8.4%
Net Profit Margin-4,605.3%-19,925.0%--

How much money comes from the company's main activities?

3. Financial Health of Abliva (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#726 / 1016

Most Revenue
#706 / 1016

Most Profit
#306 / 1016

Most Efficient
#907 / 1016

What can you expect buying and holding a share of Abliva? (5 min.)

Welcome investor! Abliva's management wants to use your money to grow the business. In return you get a share of Abliva.

What can you expect buying and holding a share of Abliva?

First you should know what it really means to hold a share of Abliva. And how you can make/lose money.

Speculation

The Price per Share of Abliva is kr0.162. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Abliva.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Abliva, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr0.07. Based on the TTM, the Book Value Change Per Share is kr-0.02 per quarter. Based on the YOY, the Book Value Change Per Share is kr0.03 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Abliva.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps0.00-1.3%0.00-1.3%0.00-1.1%0.00-1.2%0.00-1.0%
Usd Book Value Change Per Share0.00-1.3%0.00-1.2%0.001.6%0.00-0.1%0.000.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.00-1.3%0.00-1.2%0.001.6%0.00-0.1%0.000.0%
Usd Price Per Share0.02-0.02-0.03-0.06-0.78-
Price to Earnings Ratio-2.57--2.76--3.60--9.68--243.43-
Price-to-Total Gains Ratio-10.36--11.37--5.29--13.44--677.96-
Price to Book Ratio3.67-2.44-7.27-6.76-66.92-
Price-to-Total Gains Ratio-10.36--11.37--5.29--13.44--677.96-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0147744
Number of shares67684
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (67684 shares)-136.70-7.68
Gains per Year (67684 shares)-546.80-30.73
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-547-5570-31-41
20-1094-11040-61-72
30-1640-16510-92-103
40-2187-21980-123-134
50-2734-27450-154-165
60-3281-32920-184-196
70-3828-38390-215-227
80-4374-43860-246-258
90-4921-49330-277-289
100-5468-54800-307-320

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%0.057.00.00.0%
Book Value Change Per Share0.04.00.00.0%3.09.00.025.0%6.014.00.030.0%11.029.00.027.5%15.042.00.026.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.057.00.0%
Total Gains per Share0.04.00.00.0%3.09.00.025.0%6.014.00.030.0%11.029.00.027.5%15.042.00.026.3%

Fundamentals of Abliva

About Abliva AB

Abliva AB (publ), a clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

Fundamental data was last updated by Penke on 2024-04-19 00:20:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Abliva AB.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Abliva earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Abliva to the Biotechnology industry mean.
  • A Net Profit Margin of -18,421.2% means that kr-184.21 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Abliva AB:

  • The MRQ is -18,421.2%. The company is making a huge loss. -2
  • The TTM is -4,605.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-18,421.2%TTM-4,605.3%-13,815.9%
TTM-4,605.3%YOY-19,925.0%+15,319.7%
TTM-4,605.3%5Y-35,176.1%+30,570.8%
5Y-35,176.1%10Y-29,096.9%-6,079.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-18,421.2%-197.2%-18,224.0%
TTM-4,605.3%-210.4%-4,394.9%
YOY-19,925.0%-279.3%-19,645.7%
5Y-35,176.1%-436.8%-34,739.3%
10Y-29,096.9%-599.3%-28,497.6%
1.1.2. Return on Assets

Shows how efficient Abliva is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Abliva to the Biotechnology industry mean.
  • -28.8% Return on Assets means that Abliva generated kr-0.29 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Abliva AB:

  • The MRQ is -28.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -21.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-28.8%TTM-21.1%-7.8%
TTM-21.1%YOY-17.7%-3.4%
TTM-21.1%5Y-18.5%-2.5%
5Y-18.5%10Y-14.6%-3.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-28.8%-13.6%-15.2%
TTM-21.1%-12.9%-8.2%
YOY-17.7%-11.9%-5.8%
5Y-18.5%-14.2%-4.3%
10Y-14.6%-16.2%+1.6%
1.1.3. Return on Equity

Shows how efficient Abliva is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Abliva to the Biotechnology industry mean.
  • -35.7% Return on Equity means Abliva generated kr-0.36 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Abliva AB:

  • The MRQ is -35.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -24.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-35.7%TTM-24.4%-11.3%
TTM-24.4%YOY-37.5%+13.2%
TTM-24.4%5Y-25.6%+1.3%
5Y-25.6%10Y-19.1%-6.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-35.7%-17.0%-18.7%
TTM-24.4%-16.1%-8.3%
YOY-37.5%-15.4%-22.1%
5Y-25.6%-20.0%-5.6%
10Y-19.1%-21.1%+2.0%

1.2. Operating Efficiency of Abliva AB.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Abliva is operating .

  • Measures how much profit Abliva makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Abliva to the Biotechnology industry mean.
  • An Operating Margin of -18,005.8% means the company generated kr-180.06  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Abliva AB:

  • The MRQ is -18,005.8%. The company is operating very inefficient. -2
  • The TTM is -4,501.5%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-18,005.8%TTM-4,501.5%-13,504.4%
TTM-4,501.5%YOY-20,596.8%+16,095.3%
TTM-4,501.5%5Y-35,286.1%+30,784.6%
5Y-35,286.1%10Y-29,135.9%-6,150.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-18,005.8%-286.1%-17,719.7%
TTM-4,501.5%-224.4%-4,277.1%
YOY-20,596.8%-288.4%-20,308.4%
5Y-35,286.1%-475.2%-34,810.9%
10Y-29,135.9%-624.7%-28,511.2%
1.2.2. Operating Ratio

Measures how efficient Abliva is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 181.06 means that the operating costs are kr181.06 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Abliva AB:

  • The MRQ is 181.058. The company is inefficient in keeping operating costs low. -1
  • The TTM is 45.265. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ181.058TTM45.265+135.794
TTM45.265YOY206.210-160.945
TTM45.2655Y352.856-307.591
5Y352.85610Y280.978+71.878
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ181.0582.997+178.061
TTM45.2653.247+42.018
YOY206.2103.766+202.444
5Y352.8565.675+347.181
10Y280.9787.857+273.121

1.3. Liquidity of Abliva AB.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Abliva is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.80 means the company has kr3.80 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Abliva AB:

  • The MRQ is 3.800. The company is very able to pay all its short-term debts. +2
  • The TTM is 9.128. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.800TTM9.128-5.327
TTM9.128YOY6.391+2.737
TTM9.1285Y6.026+3.101
5Y6.02610Y5.790+0.236
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.8003.930-0.130
TTM9.1284.251+4.877
YOY6.3915.436+0.955
5Y6.0266.045-0.019
10Y5.7906.363-0.573
1.3.2. Quick Ratio

Measures if Abliva is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Abliva to the Biotechnology industry mean.
  • A Quick Ratio of 3.59 means the company can pay off kr3.59 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Abliva AB:

  • The MRQ is 3.590. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 8.900. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.590TTM8.900-5.311
TTM8.900YOY6.264+2.636
TTM8.9005Y5.908+2.993
5Y5.90810Y5.620+0.287
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.5903.629-0.039
TTM8.9004.065+4.835
YOY6.2645.397+0.867
5Y5.9085.993-0.085
10Y5.6206.277-0.657

1.4. Solvency of Abliva AB.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Abliva assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Abliva to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.19 means that Abliva assets are financed with 19.2% credit (debt) and the remaining percentage (100% - 19.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Abliva AB:

  • The MRQ is 0.192. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.115. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.192TTM0.115+0.077
TTM0.115YOY0.248-0.133
TTM0.1155Y0.144-0.030
5Y0.14410Y0.122+0.023
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1920.332-0.140
TTM0.1150.334-0.219
YOY0.2480.268-0.020
5Y0.1440.366-0.222
10Y0.1220.390-0.268
1.4.2. Debt to Equity Ratio

Measures if Abliva is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Abliva to the Biotechnology industry mean.
  • A Debt to Equity ratio of 23.7% means that company has kr0.24 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Abliva AB:

  • The MRQ is 0.237. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.133. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.237TTM0.133+0.104
TTM0.133YOY0.605-0.472
TTM0.1335Y0.234-0.101
5Y0.23410Y0.176+0.058
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2370.381-0.144
TTM0.1330.390-0.257
YOY0.6050.334+0.271
5Y0.2340.434-0.200
10Y0.1760.466-0.290

2. Market Valuation of Abliva AB

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Abliva generates.

  • Above 15 is considered overpriced but always compare Abliva to the Biotechnology industry mean.
  • A PE ratio of -2.57 means the investor is paying kr-2.57 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Abliva AB:

  • The EOD is -1.695. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.569. Based on the earnings, the company is expensive. -2
  • The TTM is -2.764. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.695MRQ-2.569+0.874
MRQ-2.569TTM-2.764+0.195
TTM-2.764YOY-3.601+0.837
TTM-2.7645Y-9.676+6.912
5Y-9.67610Y-243.434+233.758
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.695-2.315+0.620
MRQ-2.569-2.560-0.009
TTM-2.764-2.664-0.100
YOY-3.601-4.122+0.521
5Y-9.676-6.258-3.418
10Y-243.434-6.108-237.326
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Abliva AB:

  • The EOD is -60.595. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -91.828. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -24.783. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-60.595MRQ-91.828+31.233
MRQ-91.828TTM-24.783-67.045
TTM-24.783YOY-4.012-20.771
TTM-24.7835Y-14.033-10.750
5Y-14.03310Y-137.573+123.540
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-60.595-3.067-57.528
MRQ-91.828-3.251-88.577
TTM-24.783-3.545-21.238
YOY-4.012-5.595+1.583
5Y-14.033-8.315-5.718
10Y-137.573-8.708-128.865
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Abliva is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.67 means the investor is paying kr3.67 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Abliva AB:

  • The EOD is 2.420. Based on the equity, the company is underpriced. +1
  • The MRQ is 3.667. Based on the equity, the company is fair priced.
  • The TTM is 2.441. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.420MRQ3.667-1.247
MRQ3.667TTM2.441+1.226
TTM2.441YOY7.268-4.827
TTM2.4415Y6.756-4.315
5Y6.75610Y66.922-60.166
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.4201.905+0.515
MRQ3.6672.111+1.556
TTM2.4412.095+0.346
YOY7.2682.836+4.432
5Y6.7563.443+3.313
10Y66.9223.794+63.128
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Abliva AB compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.024-0.022-7%0.029-182%-0.001-95%0.000-100%
Book Value Per Share--0.0670.105-36%0.125-47%0.122-45%0.128-48%
Current Ratio--3.8009.128-58%6.391-41%6.026-37%5.790-34%
Debt To Asset Ratio--0.1920.115+67%0.248-23%0.144+33%0.122+58%
Debt To Equity Ratio--0.2370.133+78%0.605-61%0.234+1%0.176+35%
Dividend Per Share----0%-0%-0%-0%
Eps---0.024-0.023-5%-0.020-16%-0.021-13%-0.018-23%
Free Cash Flow Per Share---0.001-0.002+222%-0.038+5583%-0.020+2936%-0.019+2705%
Free Cash Flow To Equity Per Share---0.001-0.002+150%0.010-108%0.001-155%0.001-202%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---0.081--------
Intrinsic Value_10Y_min---0.572--------
Intrinsic Value_1Y_max---0.065--------
Intrinsic Value_1Y_min---0.085--------
Intrinsic Value_3Y_max---0.153--------
Intrinsic Value_3Y_min---0.233--------
Intrinsic Value_5Y_max---0.188--------
Intrinsic Value_5Y_min---0.355--------
Market Cap171120605.184-52%259321657.856247438282.496+5%304927411.738-15%711138152.044-64%9016701188.406-97%
Net Profit Margin---184.212-46.053-75%-199.250+8%-351.761+91%-290.969+58%
Operating Margin---180.058-45.015-75%-205.968+14%-352.861+96%-291.359+62%
Operating Ratio--181.05845.265+300%206.210-12%352.856-49%280.978-36%
Pb Ratio2.420-52%3.6672.441+50%7.268-50%6.756-46%66.922-95%
Pe Ratio-1.695+34%-2.569-2.764+8%-3.601+40%-9.676+277%-243.434+9376%
Price Per Share0.162-52%0.2460.234+5%0.289-15%0.673-64%8.536-97%
Price To Free Cash Flow Ratio-60.595+34%-91.828-24.783-73%-4.012-96%-14.033-85%-137.573+50%
Price To Total Gains Ratio-6.836+34%-10.360-11.365+10%-5.286-49%-13.441+30%-677.960+6444%
Quick Ratio--3.5908.900-60%6.264-43%5.908-39%5.620-36%
Return On Assets---0.288-0.211-27%-0.177-39%-0.185-36%-0.146-49%
Return On Equity---0.357-0.244-32%-0.375+5%-0.256-28%-0.191-46%
Total Gains Per Share---0.024-0.022-7%0.029-182%-0.001-95%0.000-100%
Usd Book Value--6449481.60010120008.000-36%12083908.800-47%11723577.600-45%12371314.200-48%
Usd Book Value Change Per Share---0.002-0.002-7%0.003-182%0.000-95%0.000-100%
Usd Book Value Per Share--0.0060.010-36%0.011-47%0.011-45%0.012-48%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.002-0.002-5%-0.002-16%-0.002-13%-0.002-23%
Usd Free Cash Flow---64387.291-207297.623+222%-3658875.600+5583%-1954940.405+2936%-1806277.562+2705%
Usd Free Cash Flow Per Share--0.0000.000+222%-0.003+5583%-0.002+2936%-0.002+2705%
Usd Free Cash Flow To Equity Per Share--0.0000.000+150%0.001-108%0.000-155%0.000-202%
Usd Market Cap15606199.193-52%23650135.19622566371.364+5%27809379.950-15%64855799.466-64%822323148.383-97%
Usd Price Per Share0.015-52%0.0220.021+5%0.026-15%0.061-64%0.778-97%
Usd Profit---2301614.400-2177810.400-5%-1995547.200-13%-2022446.640-12%-1770955.800-23%
Usd Revenue--12494.4003123.600+300%706.800+1668%3050.640+310%23641.320-47%
Usd Total Gains Per Share---0.002-0.002-7%0.003-182%0.000-95%0.000-100%
 EOD+3 -5MRQTTM+11 -22YOY+13 -205Y+11 -2210Y+9 -24

3.2. Fundamental Score

Let's check the fundamental score of Abliva AB based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.695
Price to Book Ratio (EOD)Between0-12.420
Net Profit Margin (MRQ)Greater than0-184.212
Operating Margin (MRQ)Greater than0-180.058
Quick Ratio (MRQ)Greater than13.590
Current Ratio (MRQ)Greater than13.800
Debt to Asset Ratio (MRQ)Less than10.192
Debt to Equity Ratio (MRQ)Less than10.237
Return on Equity (MRQ)Greater than0.15-0.357
Return on Assets (MRQ)Greater than0.05-0.288
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Abliva AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.016
Ma 20Greater thanMa 500.157
Ma 50Greater thanMa 1000.177
Ma 100Greater thanMa 2000.212
OpenGreater thanClose0.164
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in SEK. All numbers in thousands.

Summary
Total Assets87,499
Total Liabilities16,781
Total Stockholder Equity70,718
 As reported
Total Liabilities 16,781
Total Stockholder Equity+ 70,718
Total Assets = 87,499

Assets

Total Assets87,499
Total Current Assets62,162
Long-term Assets25,337
Total Current Assets
Cash And Cash Equivalents 57,664
Net Receivables 1,051
Other Current Assets 3,447
Total Current Assets  (as reported)62,162
Total Current Assets  (calculated)62,162
+/-0
Long-term Assets
Property Plant Equipment 1,542
Long-term Assets Other 10,685
Long-term Assets  (as reported)25,337
Long-term Assets  (calculated)12,227
+/- 13,110

Liabilities & Shareholders' Equity

Total Current Liabilities16,357
Long-term Liabilities424
Total Stockholder Equity70,718
Total Current Liabilities
Accounts payable 9,348
Other Current Liabilities 7,009
Total Current Liabilities  (as reported)16,357
Total Current Liabilities  (calculated)16,357
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)424
Long-term Liabilities  (calculated)0
+/- 424
Total Stockholder Equity
Common Stock52,815
Retained Earnings -888,872
Accumulated Other Comprehensive Income 803
Other Stockholders Equity 905,972
Total Stockholder Equity (as reported)70,718
Total Stockholder Equity (calculated)70,718
+/-0
Other
Cash and Short Term Investments 57,664
Common Stock Shares Outstanding 1,056,299
Liabilities and Stockholders Equity 87,499
Net Debt -57,664
Net Working Capital 45,805



Balance Sheet

Currency in SEK. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-31
> Total Assets 
0
0
0
11,290
15,777
45,891
43,238
42,160
40,494
39,394
35,885
33,823
33,063
78,422
72,952
71,506
66,400
64,335
58,914
89,177
155,834
136,586
133,546
131,268
196,639
238,470
191,109
174,927
169,766
226,209
192,978
180,717
154,884
134,969
123,851
120,106
108,242
144,850
129,692
115,308
204,646
189,763
170,182
148,492
119,895
160,395
162,477
150,663
137,048
183,040
99,903
58,918
61,686
182,606
203,674
183,829
156,650
142,021
109,003
87,499
87,499109,003142,021156,650183,829203,674182,60661,68658,91899,903183,040137,048150,663162,477160,395119,895148,492170,182189,763204,646115,308129,692144,850108,242120,106123,851134,969154,884180,717192,978226,209169,766174,927191,109238,470196,639131,268133,546136,586155,83489,17758,91464,33566,40071,50672,95278,42233,06333,82335,88539,39440,49442,16043,23845,89115,77711,290000
   > Total Current Assets 
0
0
0
3,447
6,268
35,663
31,133
28,646
24,993
21,155
16,661
13,679
10,696
51,603
44,253
38,136
28,284
24,039
15,781
41,601
99,250
75,706
68,206
51,323
106,855
140,371
118,039
99,558
84,169
136,596
115,128
96,072
68,816
48,687
36,868
32,527
19,869
55,257
40,238
28,627
117,145
101,233
81,690
59,919
31,399
72,128
74,616
63,157
50,106
96,434
65,099
24,254
27,278
147,602
169,154
149,816
122,950
108,936
84,019
62,162
62,16284,019108,936122,950149,816169,154147,60227,27824,25465,09996,43450,10663,15774,61672,12831,39959,91981,690101,233117,14528,62740,23855,25719,86932,52736,86848,68768,81696,072115,128136,59684,16999,558118,039140,371106,85551,32368,20675,70699,25041,60115,78124,03928,28438,13644,25351,60310,69613,67916,66121,15524,99328,64631,13335,6636,2683,447000
       Cash And Cash Equivalents 
0
0
0
2,716
4,729
33,098
29,924
27,753
23,801
19,897
15,819
12,795
9,961
49,422
43,565
37,177
27,719
22,971
14,995
39,992
97,097
74,512
58,944
49,698
104,735
138,049
116,966
96,662
78,749
132,280
112,889
93,251
67,289
46,984
35,436
28,992
15,757
51,896
38,371
25,951
113,339
99,079
79,773
58,319
29,568
69,109
73,188
61,643
47,976
94,146
63,267
22,339
23,880
135,159
73,444
66,392
59,518
63,770
58,637
57,664
57,66458,63763,77059,51866,39273,444135,15923,88022,33963,26794,14647,97661,64373,18869,10929,56858,31979,77399,079113,33925,95138,37151,89615,75728,99235,43646,98467,28993,251112,889132,28078,74996,662116,966138,049104,73549,69858,94474,51297,09739,99214,99522,97127,71937,17743,56549,4229,96112,79515,81919,89723,80127,75329,92433,0984,7292,716000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
78,949
0
0
0
0
000078,9490000000000000000000000000000000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,312
1,141
1,211
1,366
1,101
928
1,071
1,325
1,088
912
1,328
9,815
94,583
849
60,731
42,537
24,017
1,051
1,05124,01742,53760,73184994,5839,8151,3289121,0881,3251,0719281,1011,3661,2111,1411,312000000000000000000000000000000000000000000
       Other Current Assets 
0
0
0
731
1,539
2,565
1,209
893
1,192
1,258
843
884
735
2,181
688
959
565
1,068
786
1,609
2,153
1,194
9,262
1,625
2,120
2,322
1,073
2,896
5,420
4,316
2,239
2,821
1,527
1,703
1,432
3,535
4,112
3,361
1,867
2,676
3,806
2,154
1,917
1,600
1,831
3,019
1,428
1,514
2,130
2,288
1,832
1,915
3,398
1
95,710
3,626
2,701
2,629
1,365
3,447
3,4471,3652,6292,7013,62695,71013,3981,9151,8322,2882,1301,5141,4283,0191,8311,6001,9172,1543,8062,6761,8673,3614,1123,5351,4321,7031,5272,8212,2394,3165,4202,8961,0732,3222,1201,6259,2621,1942,1531,6097861,0685659596882,1817358848431,2581,1928931,2092,5651,539731000
   > Long-term Assets 
0
0
0
7,843
9,509
10,228
12,105
13,514
15,501
18,239
19,224
20,144
22,367
26,819
28,699
33,370
38,116
40,296
43,133
47,576
56,584
60,880
65,340
79,945
89,784
98,099
73,070
75,369
85,597
89,613
77,849
84,645
86,068
86,283
86,983
87,579
88,373
89,593
89,454
86,681
87,501
88,530
88,492
88,573
88,496
88,267
87,862
87,506
86,942
86,606
34,804
34,664
34,409
35,005
34,520
34,013
33,700
33,085
24,984
25,337
25,33724,98433,08533,70034,01334,52035,00534,40934,66434,80486,60686,94287,50687,86288,26788,49688,57388,49288,53087,50186,68189,45489,59388,37387,57986,98386,28386,06884,64577,84989,61385,59775,36973,07098,09989,78479,94565,34060,88056,58447,57643,13340,29638,11633,37028,69926,81922,36720,14419,22418,23915,50113,51412,10510,2289,5097,843000
       Property Plant Equipment 
0
0
0
24
34
53
46
39
44
38
30
148
157
150
736
665
595
526
487
457
385
328
268
344
482
410
347
316
285
326
290
274
196
172
187
162
157
149
167
140
1,058
1,013
899
786
684
583
482
384
288
254
157
60
49
1,072
1,001
908
1,088
986
883
1,542
1,5428839861,0889081,0011,07249601572542883844825836847868991,0131,0581401671491571621871721962742903262853163474104823442683283854574875265956657361501571483038443946533424000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
19,996
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
74,315
75,114
76,342
76,185
73,440
73,343
74,416
74,492
74,686
74,711
74,583
74,278
74,021
73,553
73,252
21,546
21,503
21,259
20,832
20,467
20,003
19,510
18,999
11,000
0
011,00018,99919,51020,00320,46720,83221,25921,50321,54673,25273,55374,02174,27874,58374,71174,68674,49274,41673,34373,44076,18576,34275,11474,3150000000000000000000000019,99600000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
155,699
0
0
0
0
0
0
0
0
0
0
51,706
51,706
51,706
51,706
51,706
51,706
51,706
51,706
51,706
0
0
-1
-1
0
1
0
0
0
0
000010-1-10051,70651,70651,70651,70651,70651,70651,70651,70651,7060000000000155,699000000000000000000000000000000
> Total Liabilities 
0
0
0
1,122
6,446
1,917
720
977
742
2,696
1,151
1,656
3,291
6,366
4,725
8,463
7,970
7,510
8,824
14,534
14,477
9,015
9,695
23,427
23,926
21,293
29,145
20,148
19,909
10,280
10,593
12,413
7,952
10,170
7,915
14,259
15,445
13,356
13,182
18,296
13,447
19,559
15,272
20,697
8,634
15,351
9,046
10,300
18,140
18,536
21,946
17,390
41,572
18,840
21,845
19,542
7,643
13,635
13,254
16,781
16,78113,25413,6357,64319,54221,84518,84041,57217,39021,94618,53618,14010,3009,04615,3518,63420,69715,27219,55913,44718,29613,18213,35615,44514,2597,91510,1707,95212,41310,59310,28019,90920,14829,14521,29323,92623,4279,6959,01514,47714,5348,8247,5107,9708,4634,7256,3663,2911,6561,1512,6967429777201,9176,4461,122000
   > Total Current Liabilities 
0
0
0
1,122
6,446
1,917
720
977
742
2,696
1,151
1,657
3,291
6,366
4,725
8,463
7,970
7,510
8,824
14,534
14,477
9,015
9,695
23,427
23,926
21,293
29,145
20,148
19,909
10,280
10,593
12,413
7,952
10,171
7,915
14,260
15,445
13,356
13,182
18,296
12,760
19,025
14,824
20,336
8,187
14,991
8,954
10,209
18,140
18,536
21,946
17,390
17,348
18,136
21,221
19,007
6,932
13,018
12,719
16,357
16,35712,71913,0186,93219,00721,22118,13617,34817,39021,94618,53618,14010,2098,95414,9918,18720,33614,82419,02512,76018,29613,18213,35615,44514,2607,91510,1717,95212,41310,59310,28019,90920,14829,14521,29323,92623,4279,6959,01514,47714,5348,8247,5107,9708,4634,7256,3663,2911,6571,1512,6967429777201,9176,4461,122000
       Short-term Debt 
0
0
0
0
6,050
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000000000000000000006,0500000
       Accounts payable 
0
0
0
919
143
1,591
351
431
224
1,713
534
817
1,519
4,446
1,274
4,724
3,294
2,977
3,862
4,759
8,211
4,352
5,000
14,216
15,484
9,717
6,312
5,207
5,555
3,934
3,642
6,000
1,653
3,657
2,336
7,525
5,350
5,263
3,698
10,162
5,120
6,250
3,915
14,234
1,769
9,258
1,736
4,201
9,049
8,856
15,587
9,616
9,289
11,990
15,524
4,860
2,922
5,440
6,044
9,348
9,3486,0445,4402,9224,86015,52411,9909,2899,61615,5878,8569,0494,2011,7369,2581,76914,2343,9156,2505,12010,1623,6985,2635,3507,5252,3363,6571,6536,0003,6423,9345,5555,2076,3129,71715,48414,2165,0004,3528,2114,7593,8622,9773,2944,7241,2744,4461,5198175341,7132244313511,591143919000
       Other Current Liabilities 
0
0
0
203
253
326
369
547
518
983
617
840
1,772
1,920
3,451
3,739
4,676
4,533
4,962
9,775
6,266
4,663
4,695
9,211
8,442
11,576
22,833
14,941
14,354
6,346
6,951
6,413
6,299
6,514
5,579
6,735
10,095
8,093
9,484
8,134
7,640
12,775
10,909
6,102
6,418
5,733
7,218
6,008
9,091
9,680
6,359
7,774
8,059
6,146
5,697
14,147
4,010
7,578
6,675
7,009
7,0096,6757,5784,01014,1475,6976,1468,0597,7746,3599,6809,0916,0087,2185,7336,4186,10210,90912,7757,6408,1349,4848,09310,0956,7355,5796,5146,2996,4136,9516,34614,35414,94122,83311,5768,4429,2114,6954,6636,2669,7754,9624,5334,6763,7393,4511,9201,772840617983518547369326253203000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1
0
-1
0
0
0
0
687
534
448
361
447
360
92
91
0
0
0
0
24,224
704
624
535
711
617
535
424
42453561771153562470424,224000091923604473614485346870000-10-1000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
534
448
0
0
-1
92
91
0
0
0
0
24,224
704
624
534
0
0
0
0
000053462470424,22400009192-10044853400000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
51,706
51,706
51,706
51,706
51,705
51,706
51,706
51,706
51,706
0
0
0
0
0
0
0
0
0
0
000000000051,70651,70651,70651,70651,70551,70651,70651,70651,70600000000000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
10,168
9,331
43,974
42,518
41,182
39,752
36,698
34,734
32,207
30,008
72,501
68,877
64,101
59,663
56,737
50,311
75,456
142,485
129,193
125,770
103,312
158,678
202,318
147,644
141,128
136,577
202,696
169,169
155,446
141,997
119,792
110,948
100,716
87,437
126,067
111,149
97,001
191,188
170,193
154,899
127,790
111,255
145,039
153,427
140,363
118,908
164,491
77,944
41,519
20,106
163,757
181,820
164,287
149,007
128,386
95,749
70,718
70,71895,749128,386149,007164,287181,820163,75720,10641,51977,944164,491118,908140,363153,427145,039111,255127,790154,899170,193191,18897,001111,149126,06787,437100,716110,948119,792141,997155,446169,169202,696136,577141,128147,644202,318158,678103,312125,770129,193142,48575,45650,31156,73759,66364,10168,87772,50130,00832,20734,73436,69839,75241,18242,51843,9749,33110,168000
   Common Stock
0
0
0
654
654
747
747
747
747
747
747
747
747
958
958
958
958
958
958
1,083
1,389
1,389
1,389
1,389
1,454
1,537
1,537
1,537
1,574
2,473
2,473
2,473
2,473
2,474
2,528
2,616
2,616
4,579
4,579
4,585
9,298
9,298
9,298
9,298
9,298
13,484
14,817
14,817
14,817
20,150
20,150
20,150
20,150
45,488
52,815
52,815
52,815
52,815
52,815
52,815
52,81552,81552,81552,81552,81552,81545,48820,15020,15020,15020,15014,81714,81714,81713,4849,2989,2989,2989,2989,2984,5854,5794,5792,6162,6162,5282,4742,4732,4732,4732,4731,5741,5371,5371,5371,4541,3891,3891,3891,3891,083958958958958958958747747747747747747747747654654000
   Retained Earnings Total Equity000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
833
827
859
224
803
8032248598278330000000000000000000000000000000000000000000000000000000
   Capital Surplus 000000000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
1,856
1,856
37,551
37,551
37,551
37,551
37,551
37,551
1,857
51,940
98,069
98,124
98,076
98,138
98,078
98,053
131,637
207,925
207,858
207,886
207,710
277,022
336,202
335,197
335,497
341,494
418,300
418,691
419,119
419,127
419,183
423,382
427,840
427,612
489,761
489,825
490,529
593,825
593,598
593,601
593,599
593,601
643,513
660,642
660,642
660,642
731,209
731,218
731,248
731,272
870,359
906,120
905,221
905,823
906,048
906,046
905,972
905,972906,046906,048905,823905,221906,120870,359731,272731,248731,218731,209660,642660,642660,642643,513593,601593,599593,601593,598593,825490,529489,825489,761427,612427,840423,382419,183419,127419,119418,691418,300341,494335,497335,197336,202277,022207,710207,886207,858207,925131,63798,05398,07898,13898,07698,12498,06951,9401,85737,55137,55137,55137,55137,55137,5511,8561,856000



Balance Sheet

Currency in SEK. All numbers in thousands.




Cash Flow

Currency in SEK. All numbers in thousands.




Income Statement

Currency in SEK. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue137
Cost of Revenue-98,030
Gross Profit-97,893-97,893
 
Operating Income (+$)
Gross Profit-97,893
Operating Expense-89,982
Operating Income-97,893-187,875
 
Operating Expense (+$)
Research Development0
Selling General Administrative0
Selling And Marketing Expenses0
Operating Expense89,9820
 
Net Interest Income (+$)
Interest Income444
Interest Expense-76
Other Finance Cost-2
Net Interest Income370
 
Pretax Income (+$)
Operating Income-97,893
Net Interest Income370
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-95,518-100,268
EBIT - interestExpense = -97,969
-95,500
-95,433
Interest Expense76
Earnings Before Interest and Taxes (EBIT)-97,893-95,442
Earnings Before Interest and Taxes (EBITDA)-87,467
 
After tax Income (+$)
Income Before Tax-95,518
Tax Provision-13
Net Income From Continuing Ops-87,849-95,531
Net Income-95,509
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses98,030
Total Other Income/Expenses Net2,375-370
 

Technical Analysis of Abliva
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Abliva. The general trend of Abliva is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Abliva's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Abliva AB.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.169 < 0.19 < 0.1902.

The bearish price targets are: 0.14 > 0.14.

Tweet this
Abliva AB Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Abliva AB. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Abliva AB Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Abliva AB. The current macd is -0.00251029.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Abliva price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Abliva. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Abliva price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Abliva AB Daily Moving Average Convergence/Divergence (MACD) ChartAbliva AB Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Abliva AB. The current adx is 27.84.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Abliva shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Abliva AB Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Abliva AB. The current sar is 0.14163486.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Abliva AB Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Abliva AB. The current rsi is 49.02. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Abliva AB Daily Relative Strength Index (RSI) ChartAbliva AB Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Abliva AB. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Abliva price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Abliva AB Daily Stochastic Oscillator ChartAbliva AB Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Abliva AB. The current cci is 81.16.

Abliva AB Daily Commodity Channel Index (CCI) ChartAbliva AB Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Abliva AB. The current cmo is 10.58.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Abliva AB Daily Chande Momentum Oscillator (CMO) ChartAbliva AB Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Abliva AB. The current willr is -24.13793103.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Abliva is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Abliva AB Daily Williams %R ChartAbliva AB Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Abliva AB.

Abliva AB Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Abliva AB. The current atr is 0.00892278.

Abliva AB Daily Average True Range (ATR) ChartAbliva AB Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Abliva AB. The current obv is 237,955,589.

Abliva AB Daily On-Balance Volume (OBV) ChartAbliva AB Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Abliva AB. The current mfi is 45.37.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Abliva AB Daily Money Flow Index (MFI) ChartAbliva AB Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Abliva AB.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-03-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.

6.3. Candlestick Patterns

Abliva AB Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Abliva AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.016
Ma 20Greater thanMa 500.157
Ma 50Greater thanMa 1000.177
Ma 100Greater thanMa 2000.212
OpenGreater thanClose0.164
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Abliva with someone you think should read this too:
  • Are you bullish or bearish on Abliva? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Abliva? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Abliva AB

I send you an email if I find something interesting about Abliva AB.


Comments

How you think about this?

Leave a comment

Stay informed about Abliva AB.

Receive notifications about Abliva AB in your mailbox!